Chronic Respiratory Disease Treatment Market Segmentation By Disease Type (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis and Others); By Drug Class (Corticosteroids, Bronchodilators, Antibiotics, Mucolytic Agents and Others); By Route of Administration (Parenteral, Oral, and Inhalational) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Demand Analysis & Opportunity Outlook 2028

  • Report ID: 1121
  • Published Date: Feb 07, 2023
  • Report Format: PDF, PPT

Introduction to Chronic Respiratory Diseases and Their Treatment

Chronic respiratory diseases are diseases of the upper respiratory tract (nose and nasal passages, paranasal sinuses, the pharynx, and the portion of the larynx above the vocal folds), lower respiratory tract (portion of the larynx below the vocal folds, trachea, bronchi and bronchioles) and the other structures of the lung. Asthma and chronic obstructive pulmonary disease (COPD) are two of the most common chronic respiratory diseases. Symptoms of such diseases include breathlessness, chronic cough, wheezing and others. The treatment for each disease vary and the ideal solution for the same is to reduce and avoid direct contact with the risk factors such as air pollution, tobacco, smoking and others. 

Market Size and Forecast

The chronic respiratory diseases treatment market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The primary factor for the growth of the market can be attributed to the increasing cases of respiratory disease worldwide. According to NCD alliance, 235 million people suffer from asthma worldwide. To cope with the large pool of patients companies are continuously working on innovating drugs to prevent or cure these diseases.

The chronic respiratory diseases treatment market is further segmented by disease type, drug class, route of administration, distribution channel and region. Disease type segment is further segmented into asthma, COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and Others. The increasing pool of patients of Asthma coupled with its high prevalence is expected to drive the market. Moreover, the popularity of inhalational type of drugs is rising on the back of its fast action and quick relief comparing to the conventional dosage forms. Thereby, the growth in these segments is expected to drive the chronic respiratory diseases market as well.

The high prevalence of diseases such as Asthma and COPD has increased the demand for drugs in hospitals and diagnostic centres. Moreover, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the global chronic respiratory diseases market is expected to grow notably over the forecast period. 


Growth Drivers

Increasing Cases of COVID-19 to Increase Demand for Respiratory Disease Drugs

Since the starting of 2020, we have witnessed an exponential growth in the number of cases of COVID-19 worldwide. In majority of the cases, patients show symptoms similar to that of respiratory diseases. Thereby, it has increased the demand for respiratory drugs. Increased demand coupled with the necessity of developing a vaccine with drive the chronic respiratory disease treatment market in upcoming few years.

Increasing Level of Air Pollution to Increase Cases for Respiratory Diseases

Most of the developing countries where rapid industrialization is happening, are witnessing an increase in the level of air pollution which is one of the primary risk factor for chronic respiratory diseases such as COPD and asthma. As per the Global Asthma report, 2018, more than 1 billion people are affected by pulmonary diseases. High level of pollution contributes to the increasing number of respiratory disease patients which can further lead to growth of chronic respiratory diseases market.


Lack of Testing Infrastructure to Diagnose Chronic Respiratory Diseases to Hamper Growth

Most of the developing nations do not have good healthcare facilities and they lack in infrastructure and COVID-19 has clearly exposed this limitation. Treatment of any disease starts only when the disease is diagnosed but the lack of testing infrastructure makes it extremely difficult to diagnose diseases among countries with high population. This limitation may hamper the market growth for respiratory diseases.

Side Effects of Drugs to Hamper Growth

Most of the respiratory disease drugs have side effects and hence people hesitate in using these drugs. So there is a challenge in-front of drug manufacturing companies to innovate and prepare drug which have either no side effects or they have only a few non-severe side effects.

Market Segmentation

Our in-depth analysis of the global chronic respiratory disease treatment market includes the following segments:

By Disease Type

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Allergic Rhinitis
  • Pulmonary Arterial Hypertension
  • Cystic Fibrosis
  • Others

By Drug Type

  • Corticosteroids
  • Bronchodilators
  • Monoclonal Antibodies
  • Antibiotics
  • Mucolytic Agents
  • Leukotriene Modifiers
  • Others

 By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

By Route of Administration

  • Parenteral
  • Oral
  • Inhalational

By Region

On the basis of regional analysis, the global chronic respiratory disease treatmentmarket is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

Currently, North America region holds the maximum market share on the back of increased awareness among the people about the respiratory diseases and the supporting government policies. The chronic respiratory diseases market is anticipated to grow significantly in Asia Pacific region during the forecast period owing to the increasing pool of the patients suffering from the disease and the rise in the air pollutants in the atmosphere.

The chronic respiratory disease treatment market is further classified on the basis of region as follows:

•   North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis

•   Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis

•   Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis

•   Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.

•   Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

  • Mylan N.V.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Teva PharmaceuticalIndustries Ltd.
  • Sunovion Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • BoehringerIngelheim Pharmaceuticals, Inc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Regeneron Pharmaceuticals, Inc.
  • Grifols, S.A.
  • Pfizer Inc.


In the News

  • March 2020 - Mylan re-started production of generic hydroxychloroquine sulfate tablets (200mg) to meet increasing demand in the context of COVID-19. Company donated 10 million tablets to US Department of Health and Human Services.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 1121
  • Published Date: Feb 07, 2023
  • Report Format: PDF, PPT

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying